Literature DB >> 12800228

PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells.

Ming-Yi Li1, Hua Deng, Jia-Ming Zhao, Dong Dai, Xiao-Yu Tan.   

Abstract

AIM: To investigate whether troglitazone (TGZ), the peroxisome proliferator-activated receptor (PPAR) gamma ligand, can induce apoptosis and inhibit cell proliferation in human liver cancer cell line HepG2 and to explore the molecular mechanisms.
METHODS: (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), ((3)H) Thymidine incorporation, Hochest33258 staining, DNA ladder, enzyme-linked immunosorbent assay (ELISA), RT-PCR, Northern and Western blotting analyses were employed to investigate the effect of TGZ on HepG2 cells and related molecular mechanisms.
RESULTS: TGZ was found to inhibit the growth of HepG2 cells and to induce apoptosis. During the process, the expression of COX-2 mRNA and protein and Bcl-2 protein was down-regulated, while that of Bax and Bak proteins was up-regulated, and the activity of caspase-3 was elevated. Furthermore, the level of PGE(2) was decreased transiently after 12 h of treatment with 30 microM troglitazone.
CONCLUSION: TGZ inhibits cell proliferation and induces apoptosis in HepG2 cells, which may be associated with the activation of caspase-3-like proteases, down-regulation of the expression of COX-2 mRNA and protein, Bcl-2 protein, the elevation of PGE2 levels, and up-regulation of the expressions of Bax and Bak proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800228      PMCID: PMC4611788          DOI: 10.3748/wjg.v9.i6.1220

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  78 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 3.  Orphan nuclear receptors--new ligands and new possibilities.

Authors:  B Blumberg; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

4.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells.

Authors:  N Takahashi; T Okumura; W Motomura; Y Fujimoto; I Kawabata; Y Kohgo
Journal:  FEBS Lett       Date:  1999-07-16       Impact factor: 4.124

6.  Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators.

Authors:  N A Callejas; A Castrillo; L Boscá; P Martín-Sanz
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

7.  PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.

Authors:  L Fajas; J C Fruchart; J Auwerx
Journal:  FEBS Lett       Date:  1998-10-30       Impact factor: 4.124

Review 8.  Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies.

Authors:  H Tapiero; G Nguyen Ba; P Couvreur; K D Tew
Journal:  Biomed Pharmacother       Date:  2002-07       Impact factor: 6.529

9.  Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer.

Authors:  Alaa F Badawi; Samy L Habib; Mohammed A Mohammed; Ahmed A Abadi; Michael S Michael
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  14 in total

1.  15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma.

Authors:  Priyadarshini Raman; Barbara L F Kaplan; Jerry T Thompson; John P Vanden Heuvel; Norbert E Kaminski
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

2.  Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.

Authors:  Mei Ming; Jie-Ping Yu; Xiang-Zhi Meng; Yan-Hong Zhou; Hong-Gang Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

3.  Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

Authors:  Suniket V Fulzele; Abhijit Chatterjee; Madhu Sudhan Shaik; Tanise Jackson; Mandip Singh
Journal:  Pharm Res       Date:  2006-08-11       Impact factor: 4.200

4.  ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells.

Authors:  Ann K Y To; George G Chen; Ursula P F Chan; Caiguo Ye; Jing P Yun; Rocky L K Ho; Art Tessier; Juanita L Merchant; Paul B S Lai
Journal:  Biochim Biophys Acta       Date:  2010-09-17

5.  The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan.

Authors:  Mao-Yu Huang; Chi-Hsiang Chung; Wei-Kuo Chang; Chun-Shu Lin; Kai-Wen Chen; Tsai-Yuan Hsieh; Wu-Chien Chien; Hsuan-Hwai Lin
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 6.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

7.  Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.

Authors:  Cai-Yan Zhao; Ling-Ling Jiang; Li Li; Zhuo-Jun Deng; Bao-Li Liang; Jian-Mei Li
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

8.  A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.

Authors:  Hong-Liang Liang; Qin Ouyang
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.

Authors:  Yan-Qin Zhang; Xiao-Qing Tang; Li Sun; Lin Dong; Yong Qin; Hua-Qing Liu; Hong Xia; Jian-Guo Cao
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

10.  Troglitazone inhibits the migration and invasion of PC-3 human prostate cancer cells by upregulating E-cadherin and glutathione peroxidase 3.

Authors:  Seo-Na Chang; Ji Min Lee; Hanseul Oh; Ukjin Kim; Bokyeong Ryu; Jae-Hak Park
Journal:  Oncol Lett       Date:  2018-08-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.